AbbVie Lands FDA Approval for Blurred-Vision Eye Drop

AbbVie’s Vuity has won FDA approval for treating age-related blurry near vision in adults — the first FDA-approved eye drop treatment for the estimated 128 million Americans with the condition.

The regulatory green light was supported by phase 3 data showing the drug provided up to six hours of improved near and intermediate vision without impacting distance vision, on day 30 of treatment.

Vuity, a pilocarpine formulation, is delivered using the company’s pHast technology which allows the drug to adjust to the physiologic pH of the eye’s tear film. Vuity works by shrinking the pupil to bolster near vision.